Estrogen alters the splicing of type 1 corticotropin-releasing hormone receptor in breast cancer cells.

Hormonal stress response is associated with the pathogenesis of disease, including cancer. The role of the stress hormone CRH (corticotropin-releasing hormone) in breast cancer is complex, and its abundance and biological activity may be modulated by estrogen. In the estrogen receptor-positive (ER+) malignant mammary epithelial cell line MCF7, CRH activated numerous kinases and downstream effectors, at least some of which were mediated by the CRH receptor type 1 (CRH-R1).

Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project.

The Sloane Project is an anonymized UK-wide audit of screen-detected atypical hyperplasia and in situ carcinoma of the breast. Full histopathology data have been provided by the local reporting pathologist on 1,684 of 2,615 cases entered to date. These include estrogen (ER), progesterone, and Her2 receptor status and the scoring/cut-off criteria for positivity used.